(GISTs), in

More documents

Recommendations

Info

ecurrence - free survival SURGERY. VIII. RECURRENCE - FREE SURVIVAL FOLLOWING TREATMENT OF PRIMARY GIST * recurrence - free survival predicted by mitotic index 1.0 0.75 0.50 0.25 0 0 p = .0001 20 40 60 80 months Singer et al J Clin Oncol 2002; 20: 3898 ≤ 3 mitoses / 30 HPF > 3 - ≤ 15 mitoses / 30 HPF > 15 mitoses / 30 HPF
SURGERY. IX. TUMOR RESECTION AS A PROGNOSTIC MARKER FOR OVERALL SURVIVAL * before availability of imatinib mesylate, poor outcome of unresectable / metastatic disease or with incomplete resection (median survival < 2 yrs)
Page 1 and 2: GASTROINTESTINAL STROMAL TUMORS * m
Page 3 and 4: ORIGIN OF GASTROINTESTINAL STROMAL
Page 5 and 6: * KIT kinase intracellular domain a
Page 7 and 8: CLINICAL PRESENTATION. I. * anywher
Page 9 and 10: PATHOLOGY
Page 11 and 12: PATHOLOGY. II. spindle cell epithel
Page 13 and 14: PATHOLOGY. IV. Historical classific
Page 15 and 16: Courtesy of Dr C Corless PATHOLOGY.
Page 17 and 18: PATHOLOGY. VIII. Assessing malignan
Page 19 and 20: Estimated proportion surviving 1.0
Page 21 and 22: DIAGNOSIS
Page 23 and 24: Initial workup for suspected or est
Page 25 and 26: ENDOSCOPY. II. Courtesy of Dr R De
Page 27 and 28: irregular submucosal mass in fundus
Page 29 and 30: COMPUTED TOMOGRAPHY. I. * diagnosis
Page 31 and 32: hepatic metastasis (hyperdense enha
Page 33 and 34: 18 FDG - PET IMAGING. II. large hep
Page 35 and 36: GIST: CT and 18 FDG - PET compariso
Page 37 and 38: TRADITIONAL TREATMENT OPTIONS
Page 39 and 40: TRADITIONAL TREATMENT. II SURGERY F
Page 41 and 42: TREATMENT. III. SURGERY OF PRIMARY
Page 43 and 44: TREATMENT. V. HEPATIC ARTERY EMBOLI
Page 45: SURGERY. VII. SURVIVAL FOLLOWING TR
Page 49 and 50: RECEPTOR TYROSINE KINASE MUTATIONS
Page 51 and 52: TYROSINE KINASES IN CANCER. II. * 2
Page 53 and 54: NORMAL KIT RECEPTOR (STEM CELL FACT
Page 55 and 56: Signalling mechanisms controlling p
Page 57 and 58: NORMAL BIOLOGIC FUNCTION OF KIT REC
Page 59 and 60: IMATINIB MESYLATE: BACKGROUND * sel
Page 61 and 62: IMATINIB MESYLATE MECHANISM OF ACTI
Page 63 and 64: IMATINIB MESYLATE SPECTRUM OF ACTIV
Page 65 and 66: IMATINIB AND BCR - ABL TK IN CHRONI
Page 67 and 68: TRANSLOCATION LEADING TO PHILADELPH
Page 69 and 70: IMATINIB TARGETS IN SOLID TUMORS. I
Page 71 and 72: IMATINIB TARGETS IN SOLID TUMORS. I
Page 73 and 74: IMATINIB TARGETS IN SOLID TUMORS. V
Page 75 and 76: IMATINIB TARGETS IN SOLID TUMORS. V
Page 77 and 78: IMATINIB TARGETS IN SOLID TUMORS. X
Page 83 and 84: % of total IMATINIB TARGETS IN SOLI
Page 89 and 90: SECONDARY CYTOGENETIC CHANGES * con
Page 91 and 92: IMATINIB TARGETS IN SOLID TUMORS GI
Page 93 and 94: IMATINIB TARGETS IN SOLID TUMORS: G
Page 95 and 96: IMATINIB TARGETS IN SOLID TUMORS GI
Page 97 and 98:
Structures of some representative s
Page 99 and 100:
Imatinib blocks KIT cancer cell KIT
Page 101 and 102:
SUNITINIB (SUTENT@ ): ORAL MULTI -
Page 103 and 104:
EFFICACY AND SAFETY OF SUNITINIB IN
Page 105 and 106:
Kaplan - Meier estimates of time to
show all

(GISTs), in

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?